On Apr. 15, 2020, Vanda Pharma announced initiation of the CALYPSO program to study the role that human genetic variations play in SARS-CoV-2 infection and disease progression. As a part of the CALYPSO program, Vanda will collaborate with University of Washington School of Medicine and its Virology Lab on a pharmacogenetics study in patients with COVID-19.

The study will focus on the sequencing of the genome of individual patients, as well as the COVID-19 virus, and the identification of genetic factors that correlate with disease progression and outcomes.